|
Not All Adverse Events in Clinical Trials Should Be Reported to IRBs
Individual adverse events in clinical trials are not necessarily the same thing as unanticipated problems and may not have to be reported as such to the institutional review board (IRB), according to new draft guidance from the FDA. This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives